Sato Waka

サトウワカ | Sato Waka

Affiliation and department：
Job title： Project Researcher

Research field (1)： Cell biology

Research theme for competitive and other funds (2)：

Papers (4)：

Waka Sato, Miho Watanabe-Takahashi, Takuya Murata, Naoko Utsunomiya-Tate, Jun Motoyama, Masataka Anzai, Seiko Ishihara, Nanako Nishioka, Hina Uchiyama, Juri Togashi, et al. A tailored tetravalent peptide displays dual functions to inhibit amyloid β production and aggregation. Communications biology. 2023. 6. 1. 383-383
Waka Sato, Mikihiko Naito. Inducing Protein Degradation to Overcome Resistance to Kinase Inhibitors. Biochemistry. 2023. 62. 3. 557-558
Waka Sato, Miho Watanabe-Takahashi, Takashi Hamabata, Koichi Furukawa, Satoru Funamoto, Kiyotaka Nishikawa. A nontoxigenic form of Shiga toxin 2 suppresses the production of amyloid β by altering the intracellular transport of amyloid precursor protein through its receptor-binding B-subunit. Biochemical and biophysical research communications. 2021. 557. 247-253
Miho Watanabe-Takahashi, Shinji Yamasaki, Masayuki Murata, Fumi Kano, Jun Motoyama, Jyoji Yamate, Jumpei Omi, Waka Sato, Hirofumi Ukai, Kentaro Shimasaki, et al. Exosome-associated Shiga toxin 2 is released from cells and causes severe toxicity in mice. Scientific reports. 2018. 8. 1. 10776-10776

MISC (3)：

佐藤和佳, 舟本聡, 西川喜代孝. Amyloid betaの産生と凝集を共に阻害するペプチド性化合物の開発. ファルマシア. 2024. 60. 8. 764-768
佐藤和佳, 内藤幹彦. 分子標的薬の幅を広げるタンパク質分解誘導薬-Targeted protein degradation that expands a range of molecular target drugs-特集新しいバイオマーカーと分子標的治療の展開. 腫瘍内科 = Clinical oncology / 腫瘍内科編集委員会編. 2023. 32. 4. 391-396
佐藤和佳, 出水庸介, 内藤幹彦. A novel type of BCR-ABL degrader to overcome the kinase inhibitor resistance. 日本がん分子標的治療学会学術集会プログラム・抄録集. 2023. 27th

Patents (1)：

Education (2)：

Professional career (1)：

Work history (1)：

Awards (4)：

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page